Gilde Healthcare leads EUR 40 Million financing in Irish healthtech company FIRE1 - Gilde Healthcare

Gilde Healthcare leads EUR 40 Million financing in Irish healthtech company FIRE1

January 30, 2018

Dublin, Ireland – Foundry Innovation & Research 1, Ltd. (“FIRE1”), today announced the close of a Series C financing totaling EUR 40 Million
($48.5 Million). The financing was led by Gilde Healthcare with the participation of Gimv, Seventure, New Enterprise Associates, Lightstone Ventures and Medtronic. It was also announced that Janke Dittmer, partner at Gilde Healthcare has joined FIRE1’s Board of Directors.

The financing provides FIRE1 with capital to further advance remote monitoring to improve outcomes for heart failure patients. Managing patients at home with novel digital health-enabled solutions will help intercept the disease trajectory and reduce hospitalizations. Nearly six million Americans live with heart failure, a number that is expect to increase to more than eight million by 2030. Globally, it is estimated that at least 26 million people suffer from heart failure, and the burden is particularly high for older patients. It is the leading cause of hospitalization for people over 65, with annual treatment costs exceeding $31 billion in the U.S. alone. With an aging population, the impact of heart failure is expected to increase substantially.

About FIRE1
Headquartered in Dublin, Ireland, FIRE1 is a connected medical device solutions company dedicated to improving outcomes for people suffering with chronic diseases. Its first product is a novel remote monitoring solution to improve outcomes for Heart Failure patients. The FIRE1 team is led by an experienced medical devices team who are working closely with researchers, clinicians, patients and payors to help reduce the burden of heart failure. For more information, please visit www.fire1foundry.com

About Gilde Healthcare
Gilde Healthcare is a specialized European healthcare investor managing two business lines: a venture & growth capital fund and a lower mid-market buy-out fund. Gilde Healthcare’s venture & growth capital fund invests in medtech, diagnostics, digital health and therapeutics. The portfolio companies are based in Europe and North America. Gilde Healthcare’s lower mid-market buy-out fund invests in profitable European healthcare services companies with a focus on the Netherlands, Belgium and Germany. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market. Since 2001 Gilde Healthcare has raised EUR 800 million (USD 1 billion) for its specialized funds. Gilde is currently investing out of Gilde Healthcare IV which is financed, in part, by the European Recovery Program-European Investment Fund Facility. For more information, visit the company’s website at www.gildehealthcare.com

Gilde Healthcare Contact:
Janke Dittmer
healthcare@gildehealthcare.com

ProVerum raises €30M in Series A funding led by Gilde Healthcare & Lightstone Ventures

ProVerum Limited, an Irish medical device company developing a minimally invasive solution to treat benign prostatic hyperplasia (BPH) in the doctor’s office, today announced the closing of a €30 million Series A equity financing led...
January 11, 2022

Gilde Healthcare portfolio Volta Medical treats first U.S. patients with persistent cardiac arrythmias

Volta Medical, a pioneering health tech company developing artificial intelligence (AI)-based software solutions to treat cardiac arrythmias, today announced the introduction of its leading-edge product, VX1, at three leading U.S. hospitals. New York Presbyterian Queens,...
December 21, 2021

Philips acquires Gilde portfolio company Vesper Medical to further expand its image-guided therapy devices portfolio

Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, today announced that it has signed an agreement to acquire Vesper Medical Inc., a US-based medical technology company that develops minimally-invasive peripheral vascular devices....
December 14, 2021